14 Best Pharma Dividend Stocks to Buy in 2026

4. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 93

Dividend Yield as of December 29: 3.00%

AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks in the pharma sector.

On December 15, BofA lowered the firm’s price target on AbbVie Inc. (NYSE:ABBV) to $233 from $248 and kept a Neutral rating. The firm said it sees “a relatively clean setup” for growth near the top end of the peer group, though that is offset by a premium valuation and limited late-stage pipeline catalysts. As part of the update, BofA shifted its valuation framework to fiscal 2027 estimates.

The stock has climbed more than 28% since the start of 2025. That move has been backed by solid financial performance. Over the first nine months of the year, revenue rose 8% from a year earlier to $44.5 billion. Adjusted earnings per share came in at $7.29, down from $7.96, largely due to acquisition-related charges. That decline is tied to timing and accounting, not to operating weakness.

Momentum should carry into 2026 and likely beyond. Early in 2024, AbbVie Inc. (NYSE:ABBV) laid out long-term guidance calling for high single-digit revenue growth through 2029. Since then, the outlook has improved in a few key areas. The biggest change has come from immunology. AbbVie originally forecast combined 2027 sales of more than $27 billion for Skyrizi and Rinvoq. That estimate has since been lifted by $4 billion. Strong demand for these two drugs remains a central driver of the company’s growth outlook through the end of the decade.

Oncology is also expected to regain traction. Management now sees revenue in that segment starting to move higher again next year, adding another layer of support to the broader growth story.

AbbVie Inc. (NYSE:ABBV) operates as a global biopharmaceutical company focused on discovering, developing, manufacturing, and selling innovative medicines for serious health conditions.